Protodigm has announced its collaboration with the Thrombosis Research Institute (TRI) on the launch of a patient study, designed to enable the development of precision medicine solutions to fight cardiovascular disease.
TRI reportedly will lead the study and:
- provide a global steering committee
- host the database and biobank
- use its clinical trial network consisting of more than 2,000 sites in 35 countries.
- enable intensive dataset interrogation of the dataset via the development of 'digital twins', machine learning algorithms, and other advanced technologies.
Also, Protodigm is set to provide pharmaceutical liaison and asymmetric learning to the study datasets. The goal is to help generate unique insights and knowledge gaps, build plans to learn, and identify potential therapeutic development paths.
Cardiovascular diseases are the leading cause of death globally, according to the World Health Organization (WHO); they claim approximately 17.9m lives around the world each year. However, according to the collaborators, the application of next-generation data science techniques stands to help abate the pervasive, deadly problem.
"This project represents a unique opportunity to follow a diverse group of patients, derive novel insights, and meaningfully improve outcomes globally in cardiovascular disease," said Vijay Kakkar, TRI president.
"Protodigm is deeply committed to applying leading-edge advances in data science and learning to accelerate insight-driven innovation,” commented Protodigm CEO Mike Rea. “The collaboration with TRI provides a unique opportunity to demonstrate this concept—this project will shape the future of big data science for our industry."
Protodigm and TRI are inviting other biotechnology and pharmaceutical companies to join their pre-competitive alliance. The study reportedly is expected to run for four years.